pDONR223-PRKAG3 Citations (2)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-PRKAG3

Articles
CDK4 Phosphorylates AMPKalpha2 to Inhibit Its Activity and Repress Fatty Acid Oxidation. Lopez-Mejia IC, Lagarrigue S, Giralt A, Martinez-Carreres L, Zanou N, Denechaud PD, Castillo-Armengol J, Chavey C, Orpinell M, Delacuisine B, Nasrallah A, Collodet C, Zhang L, Viollet B, Hardie DG, Fajas L. Mol Cell. 2017 Oct 19;68(2):336-349.e6. doi: 10.1016/j.molcel.2017.09.034. PubMed
Modulating the catalytic activity of AMPK has neuroprotective effects against alpha-synuclein toxicity. Bobela W, Nazeeruddin S, Knott G, Aebischer P, Schneider BL. Mol Neurodegener. 2017 Nov 3;12(1):80. doi: 10.1186/s13024-017-0220-x. PubMed

If you have published an article using this material, please email us at to have your article added to this page.